Selux awarded $14.6 million from BARDA for rapid antimicrobial susceptibility testing
The Biomedical Advanced Research and Development Authority (BARDA) has awarded an additional $14.6 million in funding to Selux Diagnostics for its next-generation 'phenotyping' (NGP) platform for rapid antimicrobial susceptibility testing (AST), according to a news release from Selux.
Selux received the latest round of funding after completing its first clinical trial. The company says the trial confirmed the platform’s ability to provide rapid AST results from cultured isolates in 24 hours, compared with traditional tests that take 2-3 days).
Selux plans to submit the clinical trial results to the U.S. Food and Drug Administration (FDA).
BARDA, part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the Department of Health and Human Services (HHS), modified the cost sharing contract with Selux, raising the government’s cost share of $45 million to a total level of $60.8 million if all options are exercised, the company said.
